Enzalutamide receives FDA approval for nonmetastatic CRPC

medwireNews: The US FDA has expanded the indication for enzalutamide to include men with nonmetastatic castration-resistant prostate cancer (CRPC).

Previously approved for men with metastatic CRPC, the update follows findings from the PROSPER study, where CRPC patients using the nonsteroidal anti-androgen agent achieved significantly longer metastasis-free survival than those given placebo.

Enzalutamide is recommended at a dose of 160 mg/day and is associated with side effects including fatigue, hot flash, hypertension, dizziness, nausea, and falls.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

• Androgen receptor inhibition delays CRPC metastasis
• Enzalutamide may not be contraindicated for mCRPC patients with seizure risks